PRAX
Praxis Precision Medicines, Inc.
$253.25
-0.30%
$7.1B
No data for this timeframe.
Vol
Market Cap$7.1B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (87%)
Inst. Holders9 funds
Inst. Value$1.3B
Inst. Activity6 buys / 0 sells
Reddit Sentiment50° Neutral
SEC Reports4
Press Releases4
Recent Activity
Jan 29, 2027
fda_pdufa
PDUFA: PRAX — ulixacaltamide in Essential Tremor — 2027-01-29
FDA target action date 2027-01-29 for PRAX (Praxis Precision Medicines, Inc.). Drug: ulixacaltamide.
Jun 2, 2026
Press
Praxis Precision Medicines granted 2,754 restricted stock units to 13 new non-executive employees under its 2024 Inducem
Impact 1/10
May 14, 2026
Insider
Souza Marcio sold 126 shares
Chief Executive Officer @ $167.94 ($21.2K)
May 14, 2026
Insider
Sniecinski Megan sold 89 shares
Chief Operating Officer @ $167.94 ($14.9K)
May 14, 2026
Insider
Kelly Timothy Edwin sold 121 shares
Chief Financial Officer @ $167.94 ($20.3K)
May 7, 2026
SEC
Praxis Precision Medicines reported Q1 2026 EPS of -$3.20 (GAAP), a 2.7% beat vs consensus of -$3.68, but the headline i
PRESS-RELEASE — Impact 8/10
May 4, 2026
SEC
Praxis Precision Medicines issued a press release announcing its Q1 2026 earnings report will be published on May 7, 202
PRESS-RELEASE — Impact 2/10
Feb 28, 2026
SEC
Six major institutional investors significantly increased or established new positions in Praxis Precision Medicines (PR
INST-CLUSTER — Impact 8/10
Price Targets
$627.59
+150.7% upside
Strong Buy
Current $250.33
Low $162.00
Median $550.00
High $1,201.00
17 analysts
$162.00
$1,201.00
Analyst Ratings
9Strong Buy
11Buy
2Hold
0Sell
1Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 2, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| Jun 2, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
| Jun 2, 2026 | Deutsche Bank | MAINTAIN | Buy → Buy |
| Jun 2, 2026 | Wedbush | MAINTAIN | Underperform → Underperform |
| Jun 2, 2026 | Baird | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-3.71 ▲ +2.3% | $-5.33 — $-3.04 | -12% YoY | 14 |
| Next Q | $-4.05 ▼ -2.3% | $-6.46 — $-3.30 | -21% YoY | 14 |
| Current FY | $-15.27 | $-22.94 — $-13.25 | -13% YoY | 14 |
| Next FY | $-10.18 ▼ -18.6% | $-22.60 — $3.38 | 33% YoY | 13 |
Latest Reports
NEUTRAL
Press
1/10
Praxis Precision Medicines granted 2,754 restricted stock units to 13 new non-executive employees under its 2024 Inducem
Jun 2, 2026
BULLISH
PRESS-RELEASE
8/10
Praxis Precision Medicines reported Q1 2026 EPS of -$3.20 (GAAP), a 2.7% beat vs consensus of -$3.68, but the headline i
May 7, 2026
NEUTRAL
PRESS-RELEASE
2/10
Praxis Precision Medicines issued a press release announcing its Q1 2026 earnings report will be published on May 7, 202
May 4, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $430.6M | — |
| FMR LLC | $400.5M | DOUBLED |
| MORGAN STANLEY | $262.3M | ADD |
| BANK OF AMERICA CORP | $154.1M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $58.4M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 14, 2026 | Souza Marcio | A | $21.2K |
| May 14, 2026 | Sniecinski Megan | A | $14.9K |
| May 14, 2026 | Kelly Timothy | A | $20.3K |
| May 14, 2026 | Nemiroff Alex | A | $13.1K |
| May 14, 2026 | Mastrocola Lauren | A | $21.3K |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
9 institutional holders with $1.3B total value (4,549,478 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, MORGAN. Net buying activity: 6 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,460,933 | $430.6M | 32.1% | — |
| 2 | FMR LLC | 1,358,675 | $400.5M | 29.9% | DOUBLED +3044.3% |
| 3 | MORGAN STANLEY | 889,889 | $262.3M | 19.6% | ADD +38.3% |
| 4 | BANK OF AMERICA CORP /DE/ | 522,763 | $154.1M | 11.5% | — |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 198,301 | $58.4M | 4.4% | NEW |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 66,230 | $19.5M | 1.5% | NEW |
| 7 | WELLS FARGO & COMPANY/MN | 25,235 | $7.4M | 0.6% | ADD +85.5% |
| 8 | TWO SIGMA INVESTMENTS, LP | 23,098 | $6.8M | 0.5% | DOUBLED +319.4% |
| 9 | NORGES BANK | 4,354 | $1.3M | 0.1% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | DOUBLED | 43,211 | 1,358,675 | +3044.3% | $400.5M | 2025-Q4 |
| MORGAN STANLEY | ADD | 643,495 | 889,889 | +38.3% | $262.3M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 66,230 | — | $19.5M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 13,605 | 25,235 | +85.5% | $7.4M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 5,508 | 23,098 | +319.4% | $6.8M | 2025-Q4 |
| NORGES BANK | NEW | — | 4,354 | — | $1.3M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 1,226,339 | 643,495 | -47.5% | $34.1M | 2025-Q3 |
| UBS Group AG | TRIM | 130,734 | 96,812 | -25.9% | $5.1M | 2025-Q3 |
| NORGES BANK | EXIT | 5,000 | 0 | -100.0% | $0.00 | 2025-Q3 |
| UBS Group AG | TRIM | 237,909 | 130,734 | -45.0% | $5.5M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 8,517 | 11,252 | +32.1% | $473.1K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 18,808 | 6,509 | -65.4% | $273.7K | 2025-Q2 |
| NORGES BANK | NEW | — | 5,000 | — | $210.3K | 2025-Q2 |
| UBS Group AG | ADD | 120,267 | 237,909 | +97.8% | $9.0M | 2025-Q1 |
| FMR LLC | NEAR_EXIT | 188,367 | 35,719 | -81.0% | $1.4M | 2025-Q1 |
| NORGES BANK | EXIT | 118,900 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 80,500 | 1,163,526 | +1345.4% | $89.5M | 2024-Q4 |
| CITADEL ADVISORS LLC | ADD | 96,234 | 147,790 | +53.6% | $11.4M | 2024-Q4 |
| UBS Group AG | DOUBLED | 29,550 | 120,267 | +307.0% | $9.3M | 2024-Q4 |
| NORGES BANK | DOUBLED | 5,000 | 118,900 | +2278.0% | $9.2M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 5,866 | 8,612 | +46.8% | $662.8K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 137,052 | — | $7.9M | 2024-Q3 |
| MORGAN STANLEY | TRIM | 184,319 | 80,500 | -56.3% | $4.6M | 2024-Q3 |
7 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 14, 2026 | Souza Marcio | Chief Executive Officer | A | 126 | $167.94 | $21.2K |
| May 14, 2026 | Sniecinski Megan | Chief Operating Officer | A | 89 | $167.94 | $14.9K |
| May 14, 2026 | Kelly Timothy Edwin | Chief Financial Officer | A | 121 | $167.94 | $20.3K |
| May 14, 2026 | Nemiroff Alex | General Counsel and Secretary | A | 78 | $167.94 | $13.1K |
| May 14, 2026 | Mastrocola Lauren | Principal Accounting Officer | A | 127 | $167.94 | $21.3K |
| Feb 6, 2026 | KINDLER JEFFREY B | Director | A | 224 | $0.00 | $0.00 |
| Feb 6, 2026 | KINDLER JEFFREY B | Director | A | 688 | $0.00 | $0.00 |
| Feb 6, 2026 | Arbuckle Stuart A | Director | A | 224 | $0.00 | $0.00 |
| Feb 6, 2026 | Arbuckle Stuart A | Director | A | 688 | $0.00 | $0.00 |
4 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 6.0/10.
BULLISH
PRESS-RELEASE
8/10
Praxis Precision Medicines reported Q1 2026 EPS of -$3.20 (GAAP), a 2.7% beat vs consensus of -$3.68
May 7, 2026
NEUTRAL
PRESS-RELEASE
2/10
Praxis Precision Medicines issued a press release announcing its Q1 2026 earnings report will be pub
May 4, 2026
BULLISH
INST-CLUSTER
8/10
Six major institutional investors significantly increased or established new positions in Praxis Pre
Feb 28, 2026
BULLISH
INST-CLUSTER
6/10
Three major passive institutional investors — Morgan Stanley, Wells Fargo, and UBS — significantly i
Feb 28, 2026
NEUTRAL
1/10
Praxis Precision Medicines granted 2,754 restricted stock units to 13 new non-executive employees un
Jun 2, 2026
BULLISH
8/10
Praxis Precision Medicines announced that the FDA has accepted its New Drug Application (NDA) for ul
Apr 14, 2026
BULLISH
8/10
Praxis Precision Medicines announced positive topline results from the EMBRAVE Part A trial of elsun
Apr 6, 2026
BULLISH
8/10
Praxis Precision Medicines announced FDA acceptance of its NDA for relutrigine, a first-in-class the
Mar 30, 2026
Current analyst consensus: Strong Buy (87% buy). Based on 23 analysts: 9 strong buy, 11 buy, 2 hold, 0 sell, 1 strong sell.
Analyst Price Targets
$627.59 mean target
+150.7% upside
Strong Buy (1.47)
$162.00 Low
$1,201.00 High
| Metric | Value |
|---|---|
| Current Price | $250.33 |
| Target Low | $162.00 |
| Target Mean | $627.59 |
| Target Median | $550.00 |
| Target High | $1,201.00 |
| # Analysts | 17 |
| Recommendation | Strong Buy (1.47) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-3.71 | $-5.33 | $-3.04 | -12.1% | +2.3% | 4↑ 8↓ | $0.0B | 0.0% | 14 |
| Next Q 2026-09-30 |
$-4.05 | $-6.46 | $-3.30 | -20.6% | -2.3% | 4↑ 8↓ | $0.0B | 0.0% | 14 |
| Current FY 2026-12-31 |
$-15.27 | $-22.94 | $-13.25 | -13.3% | -0.3% | 6↑ 8↓ | $0.0B | 0.0% | 14 |
| Next FY 2027-12-31 |
$-10.18 | $-22.60 | $3.38 | 33.3% | -18.6% | 5↑ 5↓ | $0.3B | 7402.2% | 13 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-3.711 | |
| 7d ago | $-3.694 | -0.017 |
| 30d ago | $-3.797 | +0.086 |
| 60d ago | $-3.794 | +0.083 |
| 90d ago | $-3.794 | +0.083 |
12 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 2, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Jun 2, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Jun 2, 2026 | Deutsche Bank | MAINTAIN | Buy | Buy |
| Jun 2, 2026 | Wedbush | MAINTAIN | Underperform | Underperform |
| Jun 2, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| Jun 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jun 2, 2026 | BTIG | MAINTAIN | Buy | Buy |
| May 26, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 20, 2026 | BTIG | REITERATE | Buy | Buy |
| May 13, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| May 8, 2026 | Wedbush | MAINTAIN | Underperform | Underperform |
| May 8, 2026 | BTIG | REITERATE | Buy | Buy |
| Apr 14, 2026 | Needham | REITERATE | Buy | Buy |
| Apr 7, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 6, 2026 | BTIG | REITERATE | Buy | Buy |
| Feb 24, 2026 | Wolfe Research | INITIATE | — | Outperform |
| Feb 20, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Feb 20, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| Feb 20, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Feb 20, 2026 | Wedbush | MAINTAIN | Underperform | Underperform |
| Feb 10, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Feb 4, 2026 | Needham | MAINTAIN | Buy | Buy |
| Feb 2, 2026 | Wells Fargo | INITIATE | — | Equal-Weight |
| Jan 30, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 28, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jan 12, 2026 | Wedbush | MAINTAIN | Underperform | Underperform |
| Dec 29, 2025 | BTIG | MAINTAIN | Buy | Buy |
| Dec 15, 2025 | Oppenheimer | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 9 | 11 | 2 | 0 | 1 | 87% | |
| May 1, 2026 | 9 | 11 | 2 | 0 | 1 | 87% | |
| Apr 1, 2026 | 8 | 11 | 2 | 0 | 1 | 86% | |
| Mar 1, 2026 | 8 | 12 | 2 | 0 | 1 | 87% | |
| Feb 1, 2026 | 7 | 12 | 1 | 0 | 1 | 90% | |
| Jan 1, 2026 | 7 | 12 | 1 | 0 | 1 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
3 mentions
0 bullish
0 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 31, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 31, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Feb 25, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Jan 29, 2027
fda_pdufa
PDUFA: PRAX — ulixacaltamide in Essential Tremor — 2027-01-29
FDA target action date 2027-01-29 for PRAX (Praxis Precision Medicines, Inc.). Drug: ulixacaltamide. Indication: Essential Tremor. FDA accepted NDA fo
Sep 27, 2026
fda_pdufa
PDUFA: PRAX — relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies — 2026-09-27
FDA target action date 2026-09-27 for PRAX (Praxis Precision Medicines, Inc.). Drug: relutrigine. Indication: SCN2A and SCN8A developmental and epilep
Jun 4, 2026
other
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
<p align="left">BOSTON, June 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=_kcvXLmzZYfJ_cQTmaNQWB8pKLq2RGx7j3CKuK
Jun 2, 2026
activist
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="left">BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervo
Jun 1, 2026
other
Praxis Precision Medicines Provides Vormatrigine Program Update
<p align="center"><em>POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure</em></p>
May 13, 2026
earnings_calendar
PRAX Q1 2026 Earnings Scheduled — 2026-05-13
May 7, 2026
earnings
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
<p align="center"><em>FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29
May 7, 2026
earnings_calendar
PRAX Q1 2026 Earnings Scheduled — 2026-05-07
May 5, 2026
other
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="left">BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervou
May 4, 2026
earnings
Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference
<p align="left">BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervou
Apr 30, 2026
earnings_calendar
PRAX Q1 2026 Earnings Scheduled — 2026-04-30
Apr 14, 2026
fda
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
<p align="center"><em>FDA assigned PDUFA target action date of January 29, 2027</em></p>
Apr 6, 2026
fda
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
<p align="center"><em>Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015)</em></p>
Apr 2, 2026
other
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="left">BOSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nerv
Mar 30, 2026
fda
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
<p align="center"><em>FDA assigned PDUFA target action date of September 27, 2026</em></p>